The Potential Applications of T Cell Receptor (TCR)-like Antibody in Cervical Cancer Immunotherapy

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2021 May 14

PMID 33989511

Citations 3

Authors

Sylvia Annabel Dass

Rehasri Selva Rajan

Gee Jun Tye

Venugopal Balakrishnan

Affiliations

Soon will be listed here.

Abstract

Cervical cancer is ranked as the fourth most common cancer in women worldwide. Monoclonal antibody has created a new dimension in the immunotherapy of many diseases, including cervical cancer. The antibody's ability to target various aspects of cervical cancer (oncoviruses, oncoproteins, and signaling pathways) delivers a promising future for efficient immunotherapy. Besides, technologies such as hybridoma and phage display provide a fundamental platform for monoclonal antibody generation and create the opportunity to generate novel antibody classes including, T cell receptor (TCR)-like antibody. In this review, the current immunotherapy strategies for cervical cancer are presented. We have also proposed a novel concept of T cell receptor (TCR)-like antibody and its potential applications for enhancing cervical cancer therapeutics. Finally, the possible challenges in TCR-like antibody application for cervical cancer therapeutics have been addressed, and strategies to overcome the challenges have been highlighted to maximize the therapeutic benefits.

Citing Articles

Challenges in the Diagnosis and Individualized Treatment of Cervical Cancer.

Schubert M, Bauerschlag D, Muallem M, Maass N, Alkatout I Medicina (Kaunas). 2023; 59(5).

PMID: 37241157 PMC: 10224285. DOI: 10.3390/medicina59050925.

TCR-like antibodies targeting autoantigen-mhc complexes: a mini-review.

Li Y, Jiang W, Mellins E Front Immunol. 2022; 13:968432.

PMID: 35967436 PMC: 9363607. DOI: 10.3389/fimmu.2022.968432.

The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.

Dass S, Balakrishnan V, Arifin N, Lim C, Nordin F, Tye G Front Immunol. 2022; 13:833715.

PMID: 35242137 PMC: 8886238. DOI: 10.3389/fimmu.2022.833715.

References

Kanodia S, Fahey L, Kast W . Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets. 2007; 7(1):79-89. DOI: 10.2174/156800907780006869. View

Friedman C, Snyder Charen A, Zhou Q, Carducci M, Buckley de Meritens A, Corr B . Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer. 2020; 8(2). PMC: 7534695. DOI: 10.1136/jitc-2020-001126. View

Zhou C, Tuong Z, Frazer I . Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System. Front Oncol. 2019; 9:682. PMC: 6688195. DOI: 10.3389/fonc.2019.00682. View

Yang X, Xie S, Yang X, Cueva J, Hou X, Tang Z . Opportunities and Challenges for Antibodies against Intracellular Antigens. Theranostics. 2019; 9(25):7792-7806. PMC: 6831482. DOI: 10.7150/thno.35486. View

He Q, Jiang X, Zhou X, Weng J . Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 2019; 12(1):139. PMC: 6921533. DOI: 10.1186/s13045-019-0812-8. View

Ataie N, Xiang J, Cheng N, Brea E, Lu W, Scheinberg D . Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics. J Mol Biol. 2015; 428(1):194-205. PMC: 4738012. DOI: 10.1016/j.jmb.2015.12.002. View

Dass S, Norazmi M, Acosta A, Sarmiento M, Tye G . TCR-like domain antibody against Mycobacterium tuberculosis (Mtb) heat shock protein antigen presented by HLA-A*11 and HLA-A*24. Int J Biol Macromol. 2020; 155:305-314. DOI: 10.1016/j.ijbiomac.2020.03.229. View

Goncalves M, Donadi E . Immune cellular response to HPV: current concepts. Braz J Infect Dis. 2004; 8(1):1-9. View

Pal A, Kundu R . Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020; 10:3116. PMC: 6985034. DOI: 10.3389/fmicb.2019.03116. View

10.

Luo Q, Zhang S, Wei H, Pang X, Zhang H . Roles of Foxp3 in the occurrence and development of cervical cancer. Int J Clin Exp Pathol. 2015; 8(8):8717-30. PMC: 4583848. View

11.

Santin A, Sill M, McMeekin D, Leitao Jr M, Brown J, Sutton G . Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2011; 122(3):495-500. PMC: 3152667. DOI: 10.1016/j.ygyno.2011.05.040. View

12.

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

13.

Mayadev J, Nunes A, Li M, Marcovitz M, Lanasa M, Monk B . CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer. 2020; 30(7):1065-1070. PMC: 7398223. DOI: 10.1136/ijgc-2019-001135. View

14.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y . Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015; 33(10):1079-86. PMC: 4600043. DOI: 10.1038/nbt.3349. View

15.

Eskander R, Tewari K . Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol. 2015; 11(6):909-22. PMC: 5613942. DOI: 10.2217/fon.14.276. View

16.

Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Tamaya T . Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br J Cancer. 2004; 91(3):466-9. PMC: 2409847. DOI: 10.1038/sj.bjc.6601963. View

17.

Jiang Y, Li Y, Zhu B . T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015; 6:e1792. PMC: 4669840. DOI: 10.1038/cddis.2015.162. View

18.

Braaten K, Laufer M . Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. Rev Obstet Gynecol. 2008; 1(1):2-10. PMC: 2492590. View

19.

Yim E, Park J . The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2009; 37(6):319-24. PMC: 2785934. DOI: 10.4143/crt.2005.37.6.319. View

20.

Chang A, Gejman R, Brea E, Oh C, Mathias M, Pankov D . Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther. 2016; 16(8):979-87. PMC: 4936943. DOI: 10.1080/14712598.2016.1176138. View